{"id":"naloxone-and-docusate","safety":{"commonSideEffects":[{"rate":null,"effect":"Withdrawal symptoms (naloxone)"},{"rate":null,"effect":"Abdominal cramping (docusate)"},{"rate":null,"effect":"Diarrhea (docusate)"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3249799","moleculeType":"Small molecule","molecularWeight":"327.38"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Naloxone is a competitive opioid receptor antagonist that rapidly displaces opioids from mu, delta, and kappa receptors, reversing respiratory depression and overdose effects. Docusate is a stool softener that reduces water loss from stool and increases intestinal fluid secretion, addressing the constipation commonly caused by chronic opioid use. This combination product is designed to mitigate both acute overdose risk and chronic opioid side effects.","oneSentence":"Naloxone reverses opioid overdose by blocking opioid receptors, while docusate softens stool to prevent opioid-induced constipation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:31.838Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid overdose reversal and prevention of opioid-induced constipation in patients on chronic opioid therapy"}]},"trialDetails":[{"nctId":"NCT00799201","phase":"PHASE4","title":"Enteral Naloxone Versus a Traditional Bowel Regimen for the Prevention of Opioid Induced Constipation in Trauma Patients","status":"TERMINATED","sponsor":"CAMC Health System","startDate":"2007-08","conditions":"Constipation, Analgesia","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Narcan","Colace"],"phase":"marketed","status":"active","brandName":"Naloxone and Docusate","genericName":"Naloxone and Docusate","companyName":"CAMC Health System","companyId":"camc-health-system","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Naloxone reverses opioid overdose by blocking opioid receptors, while docusate softens stool to prevent opioid-induced constipation. Used for Opioid overdose reversal and prevention of opioid-induced constipation in patients on chronic opioid therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}